Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ATNF

ATNF - 180 Life Sciences Corp. Stock Price, Fair Value and News

0.20USD+0.01 (+5.26%)Market Closed
Watchlist

Market Summary

USD0.20+0.01
Market Closed
5.26%

ATNF Stock Price

View Fullscreen

ATNF RSI Chart

ATNF Valuation

Market Cap

1.5M

Price/Earnings (Trailing)

-0.04

EV/EBITDA

0.03

Price/Free Cashflow

-0.13

MarketCap/EBT

-0.03

ATNF Price/Sales (Trailing)

ATNF Profitability

Return on Equity

-31.4%

Return on Assets

-815.84%

Free Cashflow Yield

-781.82%

ATNF Fundamentals

ATNF Earnings

Earnings (TTM)

-40.5M

Earnings Growth (Yr)

52.22%

Earnings Growth (Qtr)

-178.95%

Breaking Down ATNF Revenue

Last 90 days

-44.4%

Trailing 12 Months

-93.3%

How does ATNF drawdown profile look like?

ATNF Financial Health

Current Ratio

0.7

ATNF Investor Care

Shares Dilution (1Y)

269.52%

Diluted EPS (TTM)

-14.73

Tracking the Latest Insider Buys and Sells of 180 Life Sciences Corp.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 28, 2023
feldmann marc
acquired
-
-
135,377
-
Dec 15, 2023
woody james n.
bought
4,700
0.188
25,000
chief executive officer
Dec 15, 2023
feldmann marc
sold
-4,700
0.188
-25,000
-
Sep 04, 2023
gold lawrence marshall
acquired
-
-
21,455
-
Sep 04, 2023
marrone pamela g
acquired
-
-
22,388
-
Sep 04, 2023
mcgovern jr. donald a.
acquired
-
-
25,186
-
Sep 04, 2023
ray russell t
acquired
29,178
1.36
21,455
-
Jun 01, 2023
steinman lawrence
bought
22,068
1.226
18,000
-
May 31, 2023
mcgovern jr. donald a.
bought
11,470
1.147
10,000
-
May 19, 2023
mcgovern jr. donald a.
bought
5,800
1.16
5,000
-

1–10 of 50

Which funds bought or sold ATNF recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 14, 2024
MSD Partners, L.P.
unchanged
-
-648
378
-%
Feb 14, 2024
CITADEL ADVISORS LLC
added
362
5,422
13,871
-%
Feb 14, 2024
CITADEL ADVISORS LLC
added
10.87
-125
88.00
-%
Feb 14, 2024
Royal Bank of Canada
unchanged
-
-
-
-%
Feb 14, 2024
VANGUARD GROUP INC
unchanged
-
-19,093
10,216
-%
Feb 14, 2024
AQR Arbitrage LLC
reduced
-19.11
-2,181
938
-%
Feb 14, 2024
MILLENNIUM MANAGEMENT LLC
new
-
3,723
3,723
-%
Feb 14, 2024
TWO SIGMA SECURITIES, LLC
reduced
-13.36
-351
165
-%
Feb 14, 2024
Semmax Financial Advisors Inc.
unchanged
-
-
1.00
-%

1–10 of 30

Are Funds Buying or Selling ATNF?

Are funds buying ATNF calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ATNF
No. of Funds

Unveiling 180 Life Sciences Corp.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
armistice capital, llc
9.99%
1,112,480
SC 13G
Apr 14, 2023
feldmann marc
3.4%
141,747
SC 13D/A
Feb 09, 2022
vanguard index funds
2.95%
1,004,406
SC 13G/A
Feb 09, 2022
vanguard group inc
2.95%
1,004,406
SC 13G/A
Feb 07, 2022
nanchahal jagdeep
4.5%
1,520,564
SC 13G/A
Dec 13, 2021
feldmann marc
8.2%
2,834,930
SC 13D/A
Feb 10, 2021
vanguard group inc
6.54%
1,179,639
SC 13G
Feb 08, 2021
vanguard index funds
5.93%
1,069,400
SC 13G
Dec 31, 2020
bauer ronald
9.2%
2,280,171
SC 13G
Dec 30, 2020
kbl iv sponsor llc
9.03%
2,223,365
SC 13D/A

Recent SEC filings of 180 Life Sciences Corp.

View All Filings
Date Filed Form Type Document
Feb 20, 2024
8-K
Current Report
Feb 16, 2024
424B3
Prospectus Filed
Feb 16, 2024
424B3
Prospectus Filed
Feb 16, 2024
424B3
Prospectus Filed
Feb 16, 2024
8-K
Current Report
Feb 14, 2024
SC 13G
Major Ownership Report
Feb 12, 2024
424B3
Prospectus Filed
Feb 09, 2024
EFFECT
EFFECT
Jan 31, 2024
S-1
Initial Public Offering
Jan 29, 2024
8-K
Current Report

Peers (Alternatives to 180 Life Sciences Corp.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
37.9B
9.1B
-16.59% -47.80%
-10.94
4.16
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
20.5B
1.8B
-23.99% -31.71%
-46.58
11.22
76.23% 61.08%
16.9B
2.3B
-4.89% -18.90%
115.27
7.33
15.05% 75.21%
13.7B
3.7B
-7.62% -26.87%
22.88
3.7
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.22
29.35
141.38% 4.43%
5.8B
107.9M
-3.85% 226.12%
-9.38
54.1
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-18.87
17.04
-35.86% -26.24%
3.7B
240.7M
-19.08% -10.99%
-12.61
15.54
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.89
4.25
81.69% -7.29%
579.7M
1.0B
-9.17% -57.89%
-1.06
0.55
-43.15% 58.48%
174.3M
4.9M
-14.18% -58.18%
-1.06
35.65
-57.57% 50.48%
112.6M
881.7K
289.54% 381.25%
-2.37
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

180 Life Sciences Corp. News

Latest updates
TipRanks16 Feb 202409:39 pm
The Motley Fool2 years ago

180 Life Sciences Corp. Earnings Report: Key Takeaways & Analysis

Balance Sheet
(In Thousands)
Balance Sheet
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-63.7%4,95813,66714,92219,65034,33653,35859,67762,71465,07056,26560,11255,53311,02412,62612,36851,88451,57350,23766,471118,437118,221
  Current Assets14.9%3,3712,9344,1968,9286,5154,6478,95711,20113,6344,0468,2984,0157211,186388748901209145271543
    Cash Equivalents32.6%2,6632,0092,6466,9703,5891,6255,6698,22511,6881,8366,0532,10933.0070.0098.0083.00836110135567519
  Goodwill----9,06312,29112,41112,53036,98836,89637,56137,18336,901---36,423-----
Liabilities-26.5%5,1076,9517,7838,3068,26110,56618,77323,39127,92953,54937,40325,2476,2774,1427,23813,3146,8135,4565,2034,5714,691
  Current Liabilities12.5%4,8074,2735,1225,6584,7256,96615,07719,69924,22549,79933,62221,4216,2774,1423,2139,6412,7881,4311,178546666
Shareholder's Equity1818.1%128,8156,7167,14011,34426,07542,79140,90539,32337,1412,71622,70930,28735,46735,88234,74738,5715,0005,0005,0004,0895,000
  Retained Earnings-8.9%-126,116-115,850-112,170-107,408-85,666-64,179-67,118-68,682-69,718-88,015-64,556-48,357-7,933-4,583852-37,4731,3601,3821,3931,161825
  Additional Paid-In Capital2.7%128,815125,466122,195121,638115,427108,786107,930107,187106,15489,49686,43678,00512,6809,5834,14775,8903,6393,6183,6073,8384,175
Shares Outstanding79.8%6,7383,7473,7473,7471,9591,7041,7031,7021,6361,5731,3981,309843--------
Float----25,377-25,377-271,883-20,792-------50,159---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations43.0%-1,775-3,116-3,869-2,926-3,596-3,531-2,072-5,027-4,002-4,011-6,330-3,216-53.97-192-409-2,158-216-636-307-192-268
  Share Based Compensation-------------1,506---------
Cashflow From Investing------------12,878973707-66.86-69,979-38816,65453,005144228
Cashflow From Financing-0.6%2,4472,462-4696,3965,488-494-5151,54913,729-22810,363-9,22514712.00333-38,9621,330-16,041-52,834-19917.00

ATNF Income Statement

2023-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating Expenses:    
Research and development$ 972,113$ 583,177$ 2,339,863$ 1,688,474
Research and development - related parties132,88153,347481,027158,401
General and administrative2,433,1933,418,6289,204,12210,405,933
General and administrative - related parties5,261
Total Operating Expenses3,538,1874,055,15212,025,01212,258,069
Loss From Operations(3,538,187)(4,055,152)(12,025,012)(12,258,069)
Other Income (Expense):    
Interest expense(11,634)(7,348)(34,796)(22,117)
Interest (expense) income – related parties(1,536)1,495
Loss on goodwill impairment(18,872,850)(18,872,850)
Loss on IP R&D asset impairment(9,063,000)(9,063,000)
Change in fair value of derivative liabilities2,0361,449,90869,77614,167,560
Total Other Expense, Net(9,072,598)(17,431,826)(9,028,020)(4,725,912)
Net Loss Before Income Taxes(12,610,785)(21,486,978)(21,053,032)(16,983,981)
Income tax benefit2,345,0252,345,025
Net Loss(10,265,760)(21,486,978)(18,708,007)(16,983,981)
Other Comprehensive (Loss) Income:    
Foreign currency translation adjustments51,316(1,871,072)36,712(4,507,204)
Total Comprehensive Loss$ (10,214,444)$ (23,358,050)$ (18,671,295)$ (21,491,185)
Basic and Diluted Net Loss per Common Share    
Basic (in Dollars per share)$ (1.29)$ (10.97)$ (3.31)$ (9.49)
Diluted (in Dollars per share)$ (1.29)$ (10.97)$ (3.31)$ (9.49)
Weighted Average Number of Common Shares Outstanding:    
Basic (in Shares)7,951,9541,959,0875,658,8311,790,176
Diluted (in Shares)7,951,9541,959,0875,658,8311,790,176

ATNF Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Current Assets:  
Cash$ 2,662,520$ 6,970,110
Prepaid expenses and other current assets708,3771,958,280
Total Current Assets3,370,8978,928,390
Intangible assets, net1,587,1881,658,858
In-process research and development9,063,000
Total Assets4,958,08519,650,248
Current Liabilities:  
Accounts payable1,713,1641,801,210
Accrued expenses2,375,6602,284,516
Loans payable - current portion332,8851,308,516
Derivative liabilities5,60575,381
Total Current Liabilities4,806,8445,657,782
Loans payable – noncurrent portion22,21631,189
Deferred tax liability278,3522,617,359
Total Liabilities5,107,4128,306,330
Commitments and contingencies
Stockholders’ (Deficit) Equity:  
Common stock, $0.0001 par value; 100,000,000 shares authorized; 6,738,456 and 3,746,906 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively674375
Additional paid-in capital128,815,362121,637,611
Accumulated other comprehensive income(2,848,811)(2,885,523)
Accumulated deficit(126,116,552)(107,408,545)
Total Stockholders’ (Deficit) Equity(149,327)11,343,918
Total Liabilities and Stockholders’ (Deficit) Equity4,958,08519,650,248
Series A Preferred Stock  
Stockholders’ (Deficit) Equity:  
Preferred stock
Class C Preferred Stock  
Stockholders’ (Deficit) Equity:  
Preferred stock
Class K Preferred Stock  
Stockholders’ (Deficit) Equity:  
Preferred stock
Related Parties  
Current Liabilities:  
Accounts payable – related parties51,227
Accrued expenses - related parties$ 328,303$ 188,159
ATNF
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.
 CEO
 WEBSITE180lifesciences.com
 EMPLOYEES5

180 Life Sciences Corp. Frequently Asked Questions


What is the ticker symbol for 180 Life Sciences Corp.? What does ATNF stand for in stocks?

ATNF is the stock ticker symbol of 180 Life Sciences Corp.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of 180 Life Sciences Corp. (ATNF)?

As of Wed Feb 21 2024, market cap of 180 Life Sciences Corp. is 1.42 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ATNF stock?

You can check ATNF's fair value in chart for subscribers.

What is the fair value of ATNF stock?

You can check ATNF's fair value in chart for subscribers. The fair value of 180 Life Sciences Corp. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of 180 Life Sciences Corp. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ATNF so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is 180 Life Sciences Corp. a good stock to buy?

The fair value guage provides a quick view whether ATNF is over valued or under valued. Whether 180 Life Sciences Corp. is cheap or expensive depends on the assumptions which impact 180 Life Sciences Corp.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ATNF.